Molecular Allergen Component Resolved Diagnosis to Decide Immunotherapy

Not Applicable

Recruiting

• Conditions: Asthma; Rhinitis, Allergic
• Interventions: Diagnostic Test: Standard diagnosis; Diagnostic Test: Component resolved diagnosis

• Registration Number: NCT05448066
• Lead Sponsor: Universidade do Porto

Brief Summary

Allergen immunotherapy (AIT) is used for the control of allergic diseases that are not completely responsive to avoidance strategies and/or pharmacotherapy. It is also considered the main treatment with the potential to modify allergic disease evolution. It's efficacy and safety in allergic rhinitis and asthma is supported by large systematic reviews and is recommended as a cornerstone treatment option in allergic disease. Molecular based allergy diagnosis has greatly evolved and the knowledge of molecular allergen sensitization pattern has been used to better define the allergen extract composition of AIT. However, uncertainty remains if this strategy is related to an increase of efficacy. Regulation of allergen extracts for allergen immunotherapy are currently underway in Europe, but there is still lack of standardization of relevant allergens and important differences are seen between allergenic contents.

Therefore, we aim to evaluate, in a real-life setting, the impact of using molecular-based diagnosis versus standard diagnostic tools in the efficacy of aeroallergen immunotherapy, using a pragmatic randomized controlled trial design and also to address the impact of the discrepancy between individual aeroallergen sensitization profiles and the major allergen molecular content of aeroallergen immunotherapy.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2022-04-21
• Study First Submitted QC: 2022-07-01
• Study First Posted: 2022-07-07
• Study Start: 2022-07-30
• Status Verified: 2023-06
• Last Update Submitted: 2024-05-27
• Last Update Posted: 2024-05-29
• Primary Completion: 2025-09-30
• Study Completion: 2025-12-30

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 210

Inclusion Criteria

• Individuals with medical indication for aeroallergen immunotherapy(AIT) for allergic rhinoconjunctivitis or asthma, accordingly to the AIT guidelines;
• Over 5 years of age;
• Evidence of IgE-sensitization (positive skin prick tests and / or serum specific-IgE)
• Patients have indication to AIT to house dust mites and/or grass pollen, association with other allergens is not an exclusion criteria

Read More

Exclusion Criteria

• Previously performed allergen immunotherapy
• Need the use of molecular allergen diagnosis to decide treatment and diagnostic strategy

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Standard diagnosis	Standard diagnosis	Patients followed in the allergy clinic with indication for allergen immunotherapy using only standard diagnosis.
CRD diagnosis	Component resolved diagnosis	Patients followed in the allergy clinic with indication for allergen immunotherapy decided with standard diagnostic tools and molecular based diagnosis.

Primary Outcome Measures

Name	Time	Method
Change of combined symptom and medication score (CSMS) at 52 weeks	0 to 52 weeks	Differences, in the mean change at 52 weeks, of CSMS between groups that were treated with AIT in the component resolved diagnosis versus standard diagnosis groups. CSMS is the sum of the daily symptom score (dSS, score 0 to 3) plus daily medication score (dMS; score 0 to 6)
Change of combined symptom and medication score (CSMS) at 24 weeks	0 to 24 weeks	Difference, in the mean change at 24 weeks, of CSMS between groups were treated with AIT in the component resolved diagnosis versus standard diagnosis groups.
Change of rhinitis symptoms using visual analogue scale at 52 weeks	0 to 52 weeks	Difference between groups(control vs intervention) in the mean change at 52 weeks, in the psychometric response scale. This scale is used to assess rhinoconjunctivitis discomfort and its impacts on symptom severity and need of treatment.
Change of rhinitis symptoms using visual analogue scale at 24 weeks	0 to 24 weeks	Difference between groups(control vs intervention) in the mean change at 52 weeks, in the psychometric response scale. This scale is used to assess rhinoconjunctivitis discomfort and its impacts on symptom severity and need of treatment.

Secondary Outcome Measures

Name	Time	Method
Change in Control of Allergic Rhinitis and Asthma Test (CARAT) at 24 weeks	0 to 24 weeks	Differences between groups (control vs intervention) in the mean change at 24 weeks in the scores obtained on the self-administered Portuguese validated questionnaire that assess symptoms and control of both allergic rhinitis and asthma in the previous 4 weeks. The final score ranges from 0 to 30, with scores over 24 indicating good control of asthma and allergic rhinitis, a four-point changes will be considered the minimal important difference.
Change in Control of Allergic Rhinitis and Asthma Test (CARAT) at 52 weeks	0 to 52 weeks	Differences between groups (control vs intervention) in the mean change at 52 weeks in the scores obtained on the self-administered Portuguese validated questionnaire that assess symptoms and control of both allergic rhinitis and asthma in the previous 4 weeks. The final score ranges from 0 to 30, with scores over 24 indicating good control of asthma and allergic rhinitis, a four-point changes will be considered the minimal important difference
Change in quality of life related with rhinitis and asthma at 24 weeks	0 to 24 weeks	Differences between groups regarding the self-administered version of Rhinoconjunctivitis Quality of Life Questionnaire which is validated in Portuguese for patients over 12 years at 24 weeks. A change greater than 0.5 will be considered a critically clinically significant difference
Change in the cost impact between groups	0 and 52 weeks	Direct and indirect healthcare related costs will be assessed in each of the groups before and after treatment and compared
Change in Asthma Control Test (ACT) at 52 weeks	0 to 52 weeks	Differences between control and intervention group of change in the self-report questionnaire regarding asthma symtoms that includes 5 items assessing each of the following for the previous 4 weeks. ACT score ranges from 5 (poor control of asthma) to 25 (complete control of asthma)
Change in Asthma Control Test (ACT) at 24 weeks	0 to 24 weeks	Differences between control and intervention group of change in the self-report questionnaire regarding asthma symtoms that includes 5 items assessing each of the following for the previous 4 weeks. ACT score ranges from 5 (poor control of asthma) to 25 (complete control of asthma)
Change in quality of life related with rhinitis and asthma at 52 weeks	0 to 52 weeks	Difference between groups regarding self-administered version of Rhinoconjunctivitis Quality of Life Questionnaire which is validated in Portuguese for patients over 12 years at 52 weeks. A change greater than 0.5 will be considered a critically clinically significant difference
Change in ESPIA score- patient reported opinion allergen immunotherapy at 52 weeks	0 to 52 weeks	Differences between intervention and control groups in the self-administered questionnaire with 16 questions distributed in 4 dimensions: perception of effectiveness, activities and environment, cost-benefit balance and general satisfaction at 52 weeks
Change in ESPIA score- patient reported opinion allergen immunotherapy at 24 weeks	0 to 24 weeks	Differences in the self-administered questionnaire with 16 questions distributed in 4 dimensions: perception of effectiveness, activities and environment, cost-benefit balance and general satisfaction at 24 weeks

Trial Locations

Locations (1)

Faculty of Medicine Porto University/Centro Hospitalar de São João; 🇵🇹 Porto, Portugal